<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83872">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01744249</url>
  </required_header>
  <id_info>
    <org_study_id>AXI-IIG-02</org_study_id>
    <secondary_id>2011-001550-29</secondary_id>
    <nct_id>NCT01744249</nct_id>
  </id_info>
  <brief_title>Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas</brief_title>
  <official_title>Phase II Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Placebo in Patients With Progressive Advanced Well-differentiated Neuroendocrine Carcinomas of Non-pancreatic Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Tumores Neuroendocrinos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol de Tumores Neuroendocrinos</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Axitinib prolongs progression-free survival of
      patients with advanced well differentiated neuroendocrine carcinomas of non-pancreatic
      origin compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>until disease progression, end of treatment or minimum 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>calculated from the date of random assignment until the date of first progressive disease or tumor-related death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (RECIST criteria) and duration of response</measure>
    <time_frame>Until disease progression, end of treatment or minimum 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical response (5-OH-Indolacetic acid and chromogranin A)</measure>
    <time_frame>Until disease progression, end of treatment or minimum 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Until death, last follow-up,  or minimum 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>Until disease progression, end of treatment or minimum 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All adverse events and serious adverse events will be monitored with regular monitoring of hematology and blood chemistry parameters and regular physical examinations. Adverse events will be evaluated continuously throughout the study. Safety and tolerability will be assessed according to the National Institute of Health/National Cancer Institute (NIH/NCI) Common Terminology Criteria for Adverse Events version 4 (CTCAE v4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>Until disease progression or after 6 months of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>The following parameters will be measured: Circulating tumor cells, circulating endothelial cells, hypertension and other biomarkers of angiogenesis(in tumor and serum).
Peripheral blood samples (9ml)  will be obtained before treatment, after 1 month since the start of treatment and after disease progression. If progression is not achieved, an additional sample will be collected after 6 months of treatment. The blood samples will be processed for mRNA extraction. Hypoxia dependant genes  and marker genes which transcription depends on the activation of VEGF,  will be analyzed using qPCR. The dynamic profile of those genes will then be analyzed in relation to the response to axitinib, evaluating their predictive value of response.
Paraffin-embedded tumor tissue will also be collected from all patients to investigate the prognostic value and predictive potential of the different intracellular pathways related to VEGFR, PDGFR and other signaling pathways.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Well-differentiated Non-pancreatic Neuroendocrine Carcinoma</condition>
  <arm_group>
    <arm_group_label>Axitinib + Sandostatin LAR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Axitinib 5 mg BID + Sandostatin LAR 30mg/28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Sandostatin LAR</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID + Sandostatin LAR 30mg/28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib</intervention_name>
    <description>Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.</description>
    <arm_group_label>Axitinib + Sandostatin LAR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sandostatin LAR</intervention_name>
    <description>Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity</description>
    <arm_group_label>Axitinib + Sandostatin LAR</arm_group_label>
    <arm_group_label>Placebo + Sandostatin LAR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.</description>
    <arm_group_label>Placebo + Sandostatin LAR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed well or moderately differentiated neuroendocrine carcinoma
             (grade I and II WHO 2010)of non-pancreatic origin

          2. Ki-67&lt;20%

          3. Metastatic or locally advanced disease (clinically or radiologically confirmed) not
             amenable to treatment with curative intent

          4. Progressive disease documented in the prior 12 months (RECIST criteria)

          5. Measurable disease

          6. Prior treatment with somatostatin analogues permitted

          7. Prior interferon therapy allowed

          8. One prior systemic chemotherapy allowed

          9. No prior VEGF- or VEGFR-targeted therapy allowed

         10. Adequate organ function as defined by the following criteria:

               -  absolute neutrophil count (ANC) ≥1500 cells/mm3;

               -  platelets ≥75,000 cells/mm3;

               -  hemoglobin ≥9.0 g/dL;

               -  AST and ALT ≤2.5 x upper limit of normal (ULN), unless there are liver
                  metastases in which case AST and ALT ≤5.0 x ULN;

               -  total bilirubin ≤1.5 x ULN;

               -  serum creatinine ≤1.5 x ULN or calculated creatinine clearance ≥60 mL/min;

               -  urinary protein &lt;2+ by urine dipstick. If dipstick is ≥2+ then a 24-hour urine
                  collection can be done and the patient may enter only if urinary protein is &lt;2 g
                  per 24 hours.

         11. Male or female, age ≥18 years.

         12. ECOG performance status of 0-2.

         13. Life expectancy of ≥12 weeks.

         14. At least 4 weeks since the end of prior systemic treatment, radiotherapy, or surgical
             procedure with resolution of all treatment-related toxicity to NCI CTCAE Version 3.0
             grade ≤1 or back to baseline except for alopecia or hypothyroidism.

         15. No evidence of preexisting uncontrolled hypertension as documented by 2 baseline
             blood pressure readings taken at least 1 hour apart. The baseline systolic blood
             pressure readings must be ≤150 mm Hg, and the baseline diastolic blood pressure
             readings must be ≤90 mm Hg. Patients whose hypertension is controlled by
             antihypertensive therapies are eligible.

         16. Women of childbearing potential must have a negative serum or urine pregnancy test
             within 3 days prior to treatment.

         17. Signed and dated informed consent document indicating that the patient (or legally
             acceptable representative) has been informed of all pertinent aspects of the trial
             prior to enrollment.

         18. Willingness and ability to comply with scheduled visits, treatment plans and study
             procedures.

        Exclusion Criteria:

          1. The following endocrine tumor types may not be included: paraganglioma, adrenal,
             thyroid, parathyroid or pituitary endocrine tumors.

          2. Major surgery in &lt;4 weeks or radiation therapy &lt;2 weeks prior to starting the study
             treatment. Prior palliative radiotherapy to metastatic lesion(s) is permitted,
             provided there is at least one measurable lesion that has not been irradiated.

          3. Gastrointestinal abnormalities including:

               -  inability to take oral medication;

               -  requirement for intravenous alimentation;

               -  prior surgical procedures affecting absorption including total gastric
                  resection;

               -  treatment for active peptic ulcer disease in the past 6 months;

               -  active gastrointestinal bleeding, unrelated to cancer, as evidenced by
                  hematemesis, hematochezia or melena in the past 3 months without evidence of
                  resolution documented by endoscopy or colonoscopy;

               -  malabsorption syndromes.

          4. Current use or anticipated need for treatment with drugs that are known potent CYP3A4
             inhibitors (ie, grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole,
             erythromycin, telithromycin, clarithromycin, indinavir, saquinavir, ritonavir,
             nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir and delavirdine)unless
             they can be substituted with a different medication with minimal inhibition of
             CYP3A4/5. The coadministration could reduce the plasmatic concentration of axitinib.

          5. Current use or anticipated need for treatment with drugs that are known CYP3A4/5
             inducers (ie, carbamazepine, dexamethasone, felbamate, phenobarbital, phenytoin,
             amobarbital, nevirapine, primidone, rifabutin, rifampin, and St.John's wort)unless
             they can be substituted with a different medication with minimal inhibition of
             CYP3A4. The coadministration could reduce the plasmatic concentration of axitinib.

          6. Requirement of anticoagulant therapy with oral vitamin K antagonists. Low-dose
             anticoagulants for maintenance of patency of central venous access devise or
             prevention of deep venous thrombosis is allowed. Therapeutic use of low molecular
             weight heparin is allowed.

          7. Active seizure disorder or evidence of brain metastases, spinal cord compression, or
             carcinomatous meningitis.

          8. A serious uncontrolled medical disorder or active infection that would impair their
             ability to receive study treatment.

          9. Any of the following within the 12 months prior to study drug administration:

             myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft,
             symptomatic congestive heart failure, cerebrovascular accident or transient ischemic
             attack and 6 months for deep vein thrombosis or pulmonary embolism.

         10. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
             (AIDS)-related illness.

         11. History of a malignancy (other than renal cell cancer) except those treated with
             curative intent for skin cancer (other than melanoma), in situ breast or in situ
             cervical cancer, or those treated with curative intent for any other cancer with no
             evidence of disease for 5 years.

         12. Dementia or significantly altered mental status that would prohibit the understanding
             or rendering of informed consent and compliance with the requirements of this
             protocol.

         13. Female patients who are pregnant or lactating, or men and women of reproductive
             potential not willing or not able to employ an effective method of birth
             control/contraception to prevent pregnancy during treatment and for 6 months after
             discontinuing study treatment The definition of effective contraception should be in
             agreement with local regulation and based on the judgment of the principal
             investigator or a designated associate.

         14. Other severe acute or chronic medical or psychiatric condition, or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration, or may interfere with the interpretation of study results, and
             in the judgment of the investigator would make the patient inappropriate for entry
             into this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Antón Aparicio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Universitario A Coruña</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paula Jiménez Fonseca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Central de Asturias</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos López, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Marques de Valdecilla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vicente Alonso Orduña, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Miguel Servet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adelaida La Casta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Donostia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Navarro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pilar Garcia Alfonso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Gregorio Marañón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge Barriuso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Encarnación González Flores, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Virgen de las Nieves</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rocio Garcia Carbonero, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Virgen del Rocio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Sastre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico San Carlos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrique Grande, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramón y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Castellano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital U 12 de Octubre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaume Capdevila, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre Teulé Vega, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO Hospitalet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesus Rodríguez Pascual, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clara Campal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beatriz Nieto Mangudo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de León</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillermo Crespo Herrero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Burgos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ángel Segura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Fe</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rocio Garcia-Carbonero, MD</last_name>
    <phone>0034 93 451 1724</phone>
    <email>rgcarbonero@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paula Jiménez Fonseca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia L'Hospitalet</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexandre Teulé, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Univ A Coruña</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luis antón Aparicio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Quindós, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jaume Capdevila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Crespo Herrero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guillermo Crespo Herrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Encarnación González Flores, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital universitario de Leon</name>
      <address>
        <city>Leon</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Nieto Mangudo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Beatriz Nieto Mangudo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Enrique Grande Pulido, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Castellano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javier Sastre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clara Campal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Rodríguez Pascual, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jesus Rodríguez Pascual, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Univ La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jorge Barriuso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pilar García Alfonso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Univ de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Miguel Navarro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia</name>
      <address>
        <city>San Sebastian</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adelaida La Casta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Arévalo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carlos López, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rocío García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ángel Segura, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ángel Segura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vicente Alonso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 7, 2013</lastchanged_date>
  <firstreceived_date>September 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carcinoid tumor</keyword>
  <keyword>axitinib</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
